Niccolò Bolli, MD, PhD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, outlines the role of genetic profiling in multiple myeloma. Dr Bolli discusses the molecular heterogeneity of molecular myeloma and its importance in disease classification as well as precision medicine and highlights venetoclax, a BCL-2 inhibitor, which is effective in only a specific molecular subtype of multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).